This hypothesis addresses the critical role of amyloid plaque and neurofibrillary tangle (NFT) co-deposition in accurately modeling Alzheimer's disease (AD) in preclinical models. The presence of both pathological hallmarks is considered essential for creating mouse models that faithfully recapitulate key features of human AD neuropathology, including the complex interplay between amyloid and tau pathology that drives disease progression. [1]
Type: Mechanistic Proposal
Confidence Level: Strong
Testability Score: 10/10
Therapeutic Potential Score: 8/10
Related Diseases: Alzheimer's Disease
| Evidence Type | Strength | Key Findings |
|---|---|---|
| Genetic | Strong | APP, PSEN1, PSEN2 mutations cause familial AD; APOE ε4 increases Aβ accumulation and reduces clearance |
| Biochemical | Strong | Aβ42/Aβ40 ratio determines aggregation propensity; soluble oligomers more toxic than fibrils |
| Neuropathological | Strong | Human AD brain shows Aβ plaques and NFT co-localization; Braak staging correlates with clinical severity |
| Animal Models | Strong | APP/PS1, 5xFAD models develop plaques; triple transgenic models show amyloid-tau interactions |
| Clinical Trials | Moderate | Anti-amyloid antibodies reduce plaques but show modest cognitive benefits (lecanemab, donanemab) |
| Imaging | Strong | Amyloid and tau PET demonstrate progressive pathology; ligand binding correlates with cognitive decline |
Hardy & Selkoe (2002) — Established the amyloid cascade hypothesis framework and identified key evidence supporting Aβ as initiating event. [2]
Busche & Hyman (2020) — Demonstrated synergistic interactions between amyloid and tau at the synaptic level, showing that Aβ induces neuronal hyperexcitability that accelerates tau pathology. [3]
Huang et al. (2022) — Showed that amyloid and tau co-deposition in mouse models recapitulates human pattern; identified mechanisms of cross-seeding between pathologies. [4]
Jack et al. (2010) — Proposed the dynamic biomarkers cascade model showing the temporal sequence of AD biomarkers from Aβ accumulation through tau-mediated neurodegeneration. [5]
De Strooper & Karran (2023) — Reviewed the cellular phase of AD, emphasizing that Aβ triggers a self-propagating tauopathy that becomes independent of amyloid. [@de strooper2023]
Clinical Trial Disappointments: Anti-amyloid antibodies (solanezumab, crenezumab) failed in late-stage trials despite reducing Aβ burden, suggesting Aβ alone is insufficient for disease modification.
Pathology Without Dementia: Many elderly individuals have substantial amyloid and tau pathology without cognitive impairment, indicating protective factors or compensatory mechanisms.
Tau-Independent Amyloid Effects: Some data suggests Aβ can cause neurodegeneration independent of tau, complicating the cascade model.
Timing Question: Whether Aβ initiates pathology in sporadic AD remains unclear, as many patients show tau pathology without clear amyloid trigger.
Amyloid plaques are extracellular aggregates of amyloid-beta (Aβ) peptides, derived from the amyloid precursor protein (APP) through proteolytic cleavage by β-secretase (BACE1) and γ-secretase. The accumulation of Aβ42 and Aβ40 peptides into plaques is considered an early event in AD pathogenesis, triggering downstream tau pathology and neuroinflammation. [2:1]
Key Molecular Pathways:
APP Processing: APP can be processed via two pathways:
Aβ Aggregation: Aβ monomers aggregate into:
Clearance Mechanisms:
Neurofibrillary tangles are intracellular inclusions composed of hyperphosphorylated tau protein. Tau normally stabilizes microtubules, but when phosphorylated at abnormal sites, it aggregates into paired helical filaments (PHFs) that disrupt neuronal transport and lead to cell death. The progression of NFT pathology follows a predictable pattern in AD, beginning in the entorhinal cortex and spreading through the hippocampus and neocortex. [5:1]
Tau Phosphorylation Biology:
| Kinase | Target Sites | Role in AD |
|---|---|---|
| GSK-3β | Ser396, Thr231, Ser9 | Primary tau kinase |
| CDK5 | Ser202, Thr205 | Neuron-specific |
| MAPK | Ser396, Ser404 | Stress-responsive |
| JNK | Thr183, Ser202 | Apoptosis-linked |
| Phosphatase | Function | AD Changes |
|---|---|---|
| PP2A | Major tau phosphatase | Reduced in AD |
| PP1 | Dephosphorylates tau | Activity altered |
| PP5 | Calcium-regulated | Variable changes |
Aβ-Induced Kinase Activation: Aβ oligomers cause neuronal hyperactivity leading to overactivation of tau kinases (GSK-3β, CDK5)
Tau-Dependent Synaptic Dysfunction: Tau mediates Aβ-induced synaptic loss through mechanisms independent of NFT formation
Microglial Cross-Talk: TREM2 variants that impair microglial clearance lead to increased Aβ and altered tau pathology
Network Propagation: Aβ and tau pathology spread along connected neural networks in a mutually reinforcing manner
Accurate AD mouse models must replicate key pathological features:
| Model | Aβ Pathology | Tau Pathology | Cognitive Deficits | Limitations |
|---|---|---|---|---|
| APP/PS1 | +++ | + | +++ | No NFT-like pathology |
| 5xFAD | +++ | ++ | +++ | No classical NFT |
| 3xTg-AD | ++ | ++ | +++ | Complex genetics |
| APP/TTA | +++ | ++ | +++ | Inducible expression |
| P301S | - | +++ | +++ | No amyloid |
| rTg4518 | - | +++ | +++ | No amyloid |
| 5xFAD/TE4 | +++ | +++ | +++ | Dual pathology model |
Model Requirements:
While most mouse models use familial AD (FAD) mutations, genetic risk factors for sporadic AD include:
| Gene | Variant | Effect on Aβ | Effect on Tau | Risk |
|---|---|---|---|---|
| APOE | ε4 | ↑ Accumulation, ↓ clearance | ↑ Propagation | 3-4x |
| TREM2 | R47H | ↓ Phagocytosis | Altered response | 2-3x |
| CLU | C-allele | ↑ Aggregation | Variable | 1.2x |
| PICALM | Various | ↑ Endocytosis | Variable | 1.1x |
| MS4A | Various | ↓ CSF Aβ42 | ↓ CSF p-tau | Variable |
| CD33 | C-allele | ↑ Microglial retention | Variable | 1.2x |
These risk factors suggest that sporadic AD may involve mechanisms beyond simple Aβ accumulation, including microglial dysfunction, lipid metabolism alterations, and immune system modulation. [6]
Understanding the relationship between amyloid and tau has critical implications for therapy:
| Approach | Target | Status | Efficacy | Limitations |
|---|---|---|---|---|
| Lecanemab | Aβ plaques | Approved | Modest (27% slowing) | ARIA, late-stage only |
| Donanemab | Aβ plaques | Approved | Modest | ARIA, limited population |
| Anti-tau antibodies | Tau oligomers | Phase 1-2 | Pending | BBB penetration |
| Tau kinase inhibitors | GSK-3β, CDK5 | Preclinical | Unknown | Toxicity |
| Tau aggregation inhibitors | PHF formation | Preclinical | Unknown | Bioavailability |
Dual-target immunotherapy: Targeting both Aβ and tau simultaneously may provide superior benefits over single-target approaches. [7]
Sequential targeting: Remove amyloid early, then target tau before widespread spread occurs.
Network protection: Maintain functional connectivity while reducing pathology burden.
Timing is critical: Intervention before significant tau spread appears necessary for meaningful clinical benefit.
| Biomarker | Measures | Utility | Status |
|---|---|---|---|
| Amyloid PET | Plaque burden | Diagnostic, monitoring | Validated |
| Tau PET | NFT burden | Diagnostic, staging | Validated |
| CSF Aβ42 | Soluble Aβ | Diagnostic | Validated |
| CSF p-tau181/217 | Tau pathology | Diagnostic, monitoring | Validated |
| Plasma p-tau217 | Tau pathology | Screening | Emerging |
| Outcome | Method | Relevance |
|---|---|---|
| Plaque burden | Histology, PET | Amyloid pathology |
| NFT burden | Histology, Tau PET | Tau pathology |
| Synaptic markers | IHC, electrophysiology | Functional status |
| Behavior | Morris water maze, Y-maze | Cognitive function |
| Network activity | LFP, calcium imaging | Circuit dysfunction |
This hypothesis is supported by multiple lines of evidence from the literature. The requirement for dual amyloid-tau pathology in accurate AD models is well-established, with many groups developing dual-pathology models to better recapitulate human disease. However, recent clinical trials targeting amyloid have shown that removing plaques alone may not halt cognitive decline, highlighting the importance of understanding tau pathology and other contributing factors. The field is moving toward combination therapies targeting both pathologies simultaneously.
C. Dirk Keene et al. Recognizing the correlation between AD lesions in human brain and mouse models. 2016. ↩︎
Hardy & Selkoe (2002) The amyloid hypothesis of AD: progress but not panacea. 2002. ↩︎ ↩︎
Busche & Hyman (2020) Synergy between amyloid and tau in Alzheimer's disease. 2020. ↩︎
Huang et al. Co-deposition of amyloid-β and tau in human brain and mouse models. 2022. ↩︎
Jack et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. 2010. ↩︎ ↩︎
Bettens K, et al. Genetic insights in Alzheimer's disease. Nat Rev Neurol. 2021. 2021. ↩︎
Mallik S, et al. Dual-targeting immunotherapy for AD. Trends Immunol. 2023. 2023. ↩︎